Astria Therapeutics Inc (ATXS) 뉴스

Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem

-- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum...

Astria Therapeutics lance l’essai pivot de phase 3 ALPHA-ORBIT du navenibart dans l’œdème angioneurotique héréditaire

-- Cet essai est conçu pour démontrer l’efficacité et la sécurité d’une administration tous les 3 mois et tous les 6 mois sur une période de...

アストリア・セラピューティクス、遺伝性血管性浮腫（HAE）治療向けナベニバートの第3相ピボタル試験ALPHA-ORBITを開始

-- 6か月の治療期間で3か月ごとおよび6か月ごとの投与の有効性と安全性を検証 -- （ビジネスワイヤ） -- アレルギーおよび免疫疾患の画期的な治療法の開...

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

-- Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- Astria...

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic...

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic...

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic...

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic...

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

-- Early Proof-of-Concept Results from the Phase 1a Trial Anticipated in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical...

Form 8-K - Current report

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

-- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors